LM-108 + penpulimab

LM-108 + penpulimab is a combination of two monoclonal antibodies under clinical investigation for the treatment of advanced solid tumors. LM-108 is a humanized monoclonal antibody developed by LaNova Medicines that targets C-C chemokine receptor type 8 (CCR8), selectively depleting tumor-infiltrating regulatory T cells (Tregs) via enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thereby enhancing anti-tumor immune responses without affecting peripheral Tregs[1][4][5]. Penpulimab, also known as AK105, is a novel human IgG1 anti-PD-1 monoclonal antibody developed by Akeso Biopharma and Chia Tai Tianqing. It features Fc mutations to eliminate Fc receptor and complement-mediated effector functions, reducing unwanted ADCC and CDC while maintaining strong Programmed cell death protein 1 (PD-1) blockade activity[6][8]. The combination aims to synergistically enhance immune-mediated tumor cell killing by both removing immunosuppressive Tregs in the tumor microenvironment (via LM-108) and blocking PD-1 mediated inhibition of effector T cells (via penpulimab). This regimen is being evaluated in phase 2 clinical trials for advanced solid tumors[3][5].